Research programme: glucocorticoid receptor modulators - Karo Pharma/Zydus Cadila

Drug Profile

Research programme: glucocorticoid receptor modulators - Karo Pharma/Zydus Cadila

Latest Information Update: 21 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Karo Bio; Zydus Cadila
  • Class Glucocorticoids
  • Mechanism of Action Glucocorticoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 02 Apr 2012 Discontinued - Preclinical for Inflammation in India (unspecified route)
  • 02 Apr 2012 Discontinued - Preclinical for Inflammation in Sweden (unspecified route)
  • 21 Mar 2011 Karo Bio and Zydus Cadila extend their research agreement
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top